A naukri.com initiative
Bioengineer
1w
272
Image Credit: Bioengineer
HER3-Targeted Antibody-Drug Conjugate Demonstrates Potential Against Treatment-Resistant Solid Tumors
- A recent international clinical trial has shown promising results for the antibody-drug conjugate (ADC) DB-1310 in treating treatment-resistant solid tumors, especially in EGFR-mutant non-small cell lung cancer (NSCLC) patients.
- DB-1310 targets the HER3 receptor on cancer cells, delivering chemotherapy directly to malignant cells while reducing systemic toxicity associated with traditional chemotherapy.
- Data from the trial, led by Dr. Aaron Lisberg at UCLA, revealed a 44% tumor response rate in EGFR-mutant NSCLC patients, with a median overall survival close to 19 months for this challenging population.
- Overall, nearly one-third of patients across different tumor types experienced tumor shrinkage with DB-1310, showcasing its broad therapeutic potential beyond lung cancer.
- DB-1310 demonstrated manageable side effects, primarily cytopenias and mild nausea, suggesting reduced off-target effects compared to conventional chemotherapy.
- The ADC's targeted mechanism leverages HER3 binding to overcome resistance mechanisms and spare healthy cells, offering precision treatment against malignancies.
- Dr. Lisberg emphasized DB-1310's promise in providing effective treatment options for patients with limited choices due to disease progression, calling it a significant step forward.
- Ongoing research aims to optimize dosing and expand the trial to diverse patient populations, with a focus on deepening understanding of DB-1310's efficacy and safety across various tumor types.
- DB-1310's potential extends to HER3-positive malignancies in breast, head and neck, and gastrointestinal cancers, highlighting its broader implications in targeted cancer therapy.
- Presented at the 2025 ASCO Annual Meeting, DB-1310's outcomes underscore the transformative role of antibody-drug conjugates in cancer treatment and their ability to enhance patient outcomes with reduced side effects.
- The collaborative efforts of researchers, clinicians, and teams worldwide have propelled DB-1310 from bench to bedside, showcasing the advancement in cancer therapeutics through translational research.
Read Full Article
16 Likes
For uninterrupted reading, download the app